Nimbus Therapeutics is a biotechnology company based in Cambridge, Massachusetts, that specializes in discovering and developing innovative small molecule therapeutics for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company employs a computational technology-driven approach to advance its diverse pipeline of drug candidates into clinical development. Its Nimbus Apollo program includes the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase, which is being investigated for treating non-alcoholic steatohepatitis and hepatocellular carcinoma, among other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, and the company aims to leverage its strategic partnerships to enhance its research and development efforts. Founded in 2009, Nimbus Therapeutics continues to focus on creating highly selective and potent medicines that address unmet medical needs.
X4 Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing novel therapeutics for primary immune deficiencies and cancer. Its lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4 and is currently undergoing various clinical trials, including a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as trials for severe congenital neutropenia and clear cell renal cell carcinoma. The company is also advancing X4P-002, which targets glioblastoma multiforme, and X4P-003, aimed at treating primary immune deficiencies. Additionally, X4 Pharmaceuticals has a collaboration with Abbisko Therapeutics to explore mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in 2019.
Hometap Equity Partners, LLC, based in Boston, Massachusetts, offers homeowners a unique financial solution by providing cash through home equity investments without the burden of debt. Founded in 2017, Hometap allows homeowners to access up to 20 percent of their home's value, enabling them to receive immediate funds for various needs without incurring interest rates, monthly payments, or credit score requirements. This innovative approach aims to enhance financial stability and freedom for homeowners, thereby transforming the traditional landscape of home financing. In addition to its investment services, Hometap also emphasizes homeowner education through a data-driven platform, further supporting its mission to change the face of homeownership.
Cardurion Pharmaceuticals, LLC is a biotechnology company based in Boston, Massachusetts, established in 2017. The company focuses on developing innovative therapeutics for heart failure and other cardiovascular diseases. In a significant partnership with Takeda Pharmaceutical Company, announced in July 2017, Cardurion aims to create next-generation treatments for these conditions, utilizing external innovation to enhance its discovery programs. Additionally, in April 2018, Cardurion entered an exclusive licensing agreement with Astellas for the development and commercialization of CRD-733, a PDE-9 inhibitor. This compound shows promise in improving cardiac function in heart failure patients by potentially restoring protective cellular mechanisms that fail in this condition.
Developer of impact investing solutions designed to increase the flow of capital into ventures solving global and local challenges. The company's services discover and make impact investments, using their donor-advised fund, family office, or private foundation assets and transform the way to find opportunities to invest money for good, enabling philanthropic and financial institutions and their clients to discover, execute and monitor impact investments.
Private Equity Round in 2021
ConvenientMD Urgent Care offers convenient access to high-quality medical care, at the most affordable rates around. Patients can just walk in, without making an appointment, from 8 am to 8 pm, seven days a week. Patients are typically in and out in under 1 hour and there is always a full medical team on site. The center has friendly staff who provide world-class customer service with state-of-the-art medical equipment, including digital x-ray, lab, EKG, and IV equipment. ConvenientMD’s expert medical team is ready and equipped to treat a broad range of injuries and illness.
ConvenientMD has NH locations in Bedford, Concord, Dover, Exeter, Keene, Merrimack, Nashua, Portsmouth, and Windham. Maine locations include Westbrook and Portland, with additional locations opening throughout New England.
Cerevel (www.cerevel.com) is a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). The company has a portfolio of pre-commercial neuroscience assets, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.
X4 Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing novel therapeutics for primary immune deficiencies and cancer. Its lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4 and is currently undergoing various clinical trials, including a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as trials for severe congenital neutropenia and clear cell renal cell carcinoma. The company is also advancing X4P-002, which targets glioblastoma multiforme, and X4P-003, aimed at treating primary immune deficiencies. Additionally, X4 Pharmaceuticals has a collaboration with Abbisko Therapeutics to explore mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in 2019.
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic disorder primarily affecting boys. The company's lead candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in muscle tissues. In addition to SGT-001, Solid Biosciences is advancing Anti-LTBP4, a monoclonal antibody designed to mitigate fibrosis and inflammation by targeting the LTBP4 protein. The company also works on developing biomarkers and wearable assistive devices under the Solid Suit program, which aims to provide therapeutic benefits to patients. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to further develop and commercialize gene therapies for DMD. The company’s initiatives address a critical need, as there are currently no effective cures or satisfactory treatments for this progressive and life-threatening condition.
Syros Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead candidates, SY-1425, a selective retinoic acid receptor alpha agonist currently undergoing Phase II trials for specific patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor in Phase I trials for select advanced solid tumors. Syros employs a proprietary platform that integrates assay technologies, bioinformatics, and biological insights to map gene regulatory circuits and modulate gene expression, positioning itself as a leader in gene control research. Additionally, Syros has established collaborations, including a target discovery agreement with Incyte Corporation focused on myeloproliferative neoplasms, and a licensing agreement with TMRC Co. Ltd. for tamibarotene's development and commercialization. Founded in 2011, Syros Pharmaceuticals aims to address significant unmet medical needs in oncology and beyond.
AavantiBio, Inc. is dedicated to developing gene transfer therapy and gene editing technologies aimed at improving the lives of individuals afflicted by rare and fatal diseases. The company primarily focuses on Friedreich’s Ataxia, a rare inherited genetic disorder that leads to significant cardiac and central nervous system dysfunction. Founded in 2019 and based in Gainesville, Florida, AavantiBio is committed to advancing innovative gene therapies to address unmet medical needs in the treatment of rare genetic diseases and autoimmune conditions. Through its research and development efforts, the company seeks to transform patient care and enhance treatment options for those affected by these serious health challenges.
Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration.
The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.
Atea Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections. It caters to the healthcare industry and engages in the discovery and development of antiviral therapeutics that enable patients to have treatment for infections caused by RNA and DNA viruses.
Atea Pharmaceuticals was established in 2014 and is headquartered in Boston, Massachusetts.
Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, that specializes in developing vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins in a single vaccine, aiming to enhance the immune response against various infectious diseases. Affinivax focuses on a range of pathogens, including Streptococcus pneumoniae, which poses significant health risks to both children and adults. The company seeks to create vaccines that provide broader disease coverage and address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from insights provided by leading experts in infectious diseases and vaccines, and it has secured support from the Bill & Melinda Gates Foundation, along with exclusive licensing rights from Boston Children’s Hospital for its MAPS technology.
Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications.
It was founded in 2005 and headquartered in Cambridge, Massachusetts.
Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, established in 2015. It specializes in targeted protein degradation, developing innovative small molecule therapeutics that selectively degrade proteins associated with various diseases by utilizing the body's natural protein degradation mechanisms. The company is advancing several therapeutic programs, including the IRAK4 program aimed at treating immunology-inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis. Additionally, it is developing the IRAKIMiD program for MYD88-mutated diffuse large B cell lymphoma and the STAT3 program for hematologic malignancies and solid tumors, as well as autoimmune diseases. Through its proprietary predictive modeling platform, Kymera Therapeutics seeks to accelerate drug discovery and address previously untreatable conditions.
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.
Marinus Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of ganaxolone, offering a new mechanism of action with safe and convenient dosing, for adult and pediatric patient populations in acute and chronic care settings.
The company was founded in 2003 and is based in Branford, Connecticut.
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics aimed at addressing significant unmet medical needs in cancer treatment, particularly those related to abnormal gene expression and drug resistance. The company's lead product candidates include CPI-0610, currently undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is in Phase Ib/II trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial for solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. and has established itself as a pioneer in the emerging field of epigenetics, which focuses on selective regulators of epigenetic function crucial for gene expression control.
IQVIA, Inc. is a global provider of information and technology services tailored for the healthcare industry. The company specializes in collecting and organizing comprehensive healthcare data, including sales, prescriptions, medical claims, and electronic medical records. IQVIA offers a range of solutions, such as IMS One, a cloud application for business analytics that allows clients to analyze healthcare data related to diseases, treatments, costs, and outcomes. Its services also include commercial applications for sales operations, real-world evidence solutions for evaluating treatment value, and clinical solutions to support the design and execution of clinical trials. The company serves a diverse clientele, including pharmaceutical manufacturers, medical device companies, providers, payers, government agencies, and researchers. Founded in 2010 and based in Danbury, Connecticut, IQVIA, Inc. operates as a subsidiary of IQVIA Holdings Inc.
SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for underserved patient populations affected by rare diseases and cancer. Founded in 2017 and headquartered in Stamford, Connecticut, the company’s lead product candidate, nirogacestat, is an oral small molecule gamma secretase inhibitor currently in Phase III trials for treating desmoid tumors. Other significant candidates include mirdametinib, an oral MEK inhibitor in Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas, and various combinations involving nirogacestat for relapsed or refractory multiple myeloma. The company is also exploring additional therapies, such as BGB-3245, an investigational oral inhibitor targeting BRAF mutations, currently in Phase I trials. SpringWorks has established collaborations with several biotechnology and pharmaceutical firms to enhance its research and development efforts.
HealthDrive, founded in 1989 by medical professionals, specializes in delivering on-site medical and dental services to residents of long-term care facilities. Recognizing the need for enhanced healthcare in these settings, the company has built a network of over 120 skilled providers, including specialists in dentistry, optometry, podiatry, and audiology. Serving more than 135,000 senior living residents across 1,000 facilities nationwide, HealthDrive focuses on providing proactive healthcare tailored to the unique needs of seniors. Their commitment to delivering services with care and empathy aims to improve the overall quality of life for individuals in long-term care. By bringing essential healthcare services directly to the facilities, HealthDrive enhances accessibility and ensures that residents receive the comprehensive care they require.
Private Equity Round in 2018
Cerevel (www.cerevel.com) is a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). The company has a portfolio of pre-commercial neuroscience assets, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.
Rocket Software, Inc. develops enterprise software solutions that address a wide range of business needs. Its offerings include products for application lifecycle management, data management, business intelligence, backup management, and modernization, among others. The company also supports the Python programming language and provides training and professional services. Serving a diverse array of industries such as automotive, healthcare, finance, and technology, Rocket Software is dedicated to helping organizations solve complex IT challenges while enhancing infrastructure, data usage, and application performance. Founded in 1990 and headquartered in Waltham, Massachusetts, Rocket Software operates globally with locations in North America, Europe, and Asia/Pacific, partnering with various hardware and software vendors to deliver innovative solutions that meet evolving market demands.
Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration.
The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.
SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for underserved patient populations affected by rare diseases and cancer. Founded in 2017 and headquartered in Stamford, Connecticut, the company’s lead product candidate, nirogacestat, is an oral small molecule gamma secretase inhibitor currently in Phase III trials for treating desmoid tumors. Other significant candidates include mirdametinib, an oral MEK inhibitor in Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas, and various combinations involving nirogacestat for relapsed or refractory multiple myeloma. The company is also exploring additional therapies, such as BGB-3245, an investigational oral inhibitor targeting BRAF mutations, currently in Phase I trials. SpringWorks has established collaborations with several biotechnology and pharmaceutical firms to enhance its research and development efforts.
Marinus Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of ganaxolone, offering a new mechanism of action with safe and convenient dosing, for adult and pediatric patient populations in acute and chronic care settings.
The company was founded in 2003 and is based in Branford, Connecticut.
Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company’s lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Private Equity Round in 2017
Impact Fitness is a leading Planet Fitness franchisee with 29 clubs across the United States and Canada. Here At Impact Fitness, We Believe In Revolutionizing The Fitness Industry. Our Gym Is A Strong, Safe, Exciting And Positive Atmosphere For Everyone. We Offer Only The Most Innovated State Of The Art Equipment, The Biggest Selection Of Free Weights, The Newest In Technology For Cardio Training And The Best In Class Group Exercise Program With An Unparalleled Level Of Commitment To Our Gym Members To Help Them Succeed In Their Fitness Goals. Impact Fitness Is A Gym For Everyone To Come And Achieve The Best They Can From Themselves, No Matter What Your Goal Is. Come See Why Our Local Gym in Auburn Is Making A Difference In How Everyone Achieves Their Fitness Goals Today!
Dicerna Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of innovative treatments primarily for liver-related diseases, including rare inherited conditions, chronic liver diseases, and viral infections. Utilizing its proprietary GalXC RNA interference technology, Dicerna focuses on silencing disease-causing genes to address various health issues. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and belcesiran for genetic liver disease, among others. The company's extensive research efforts also encompass treatments for cardiovascular diseases and neurodegeneration. Dicerna has established strategic collaborations with prominent pharmaceutical companies to enhance its development capabilities. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna is at the forefront of advancing RNA-based therapeutics.
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic disorder primarily affecting boys. The company's lead candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in muscle tissues. In addition to SGT-001, Solid Biosciences is advancing Anti-LTBP4, a monoclonal antibody designed to mitigate fibrosis and inflammation by targeting the LTBP4 protein. The company also works on developing biomarkers and wearable assistive devices under the Solid Suit program, which aims to provide therapeutic benefits to patients. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to further develop and commercialize gene therapies for DMD. The company’s initiatives address a critical need, as there are currently no effective cures or satisfactory treatments for this progressive and life-threatening condition.
Daymon Worldwide, Inc. is a global leader in consumables retailing, providing comprehensive services that enhance branding, sourcing, and commercialization for retailers. Founded in 1970 and based in Stamford, Connecticut, the company specializes in private brand development, offering services such as brand strategy, product development, supplier management, and category analytics. Daymon also delivers a range of retail services, including store remodeling, audits, and logistics management, as well as consumer experience marketing, which features in-store sampling and mystery shopping. With a network of over 39,000 associates across six continents, Daymon Worldwide collaborates with retailer customers in various sectors, including automotive, convenience stores, and e-commerce, to create customized strategies that drive sales and market share.
Founded in 1996, Blue Coat is now an industry leader in the field of advanced enterprise security. Originally founded as CacheFlow, the company changed its name to Blue Coat in 2002 to reflect its new emphasis on enterprise security, invoking the image of a baseball umpire’s uniform. In March 2015, Blue Coat was acquired by private equity firm Bain Capital. Blue Coat provides advanced enterprise security for 15,000 organizations across the globe, numbering 88 of the 100 largest global companies among them. The Blue Coat Security Platform provides an integrated platform that addresses companies’ network, security, and cloud requirements. This allows customers a minimal impact on network performance while still providing top-quality protection against advanced threats and improving performance for cloud applications and services. Blue Coat focuses strongly on growth and innovation, with 200 patents issued and pending. Blue Coat also maintains several Research and Development centers across the globe, with facilities in Sunnyvale, California; Draper, Utah; Waterloo, Ontario; Boxborough, Massachusetts; and Lysaker, Norway. The company also providers 24/7 “Follow the Sun” Model Global Support from each of its six support centers. Particularly in recent years, Blue Coat has achieved significant positive recognition within the industry, receiving many awards. Among these accolades are the Frost & Sullivan 2016 Global Network Security Forensics Market Leadership Award; the Frost & Sullivan 2014 Web Security Vendor of the Year Award; the 2015 Cloud Computing Magazine Cloud Computing Excellence Award; and the 2015 Best Cloud Computing Security Solution, Reader Trust Award from SC Magazine.
Turbonomic specializes in application resource management technology that optimizes application performance, compliance, and cost in real-time. Its AI-powered platform integrates with major application performance management (APM) and IT service management solutions, creating a control plane to automate IT resource management across on-premises and multi-cloud environments. By dynamically aligning application demand with infrastructure supply, Turbonomic enables organizations to maintain optimal application health and performance while effectively managing costs. The platform's workload automation capabilities provide a comprehensive solution for hybrid cloud environments, ensuring organizations can self-manage their resources in real-time.
SevOne, Inc. specializes in infrastructure performance monitoring and analytics solutions for a global clientele, including communications service providers, government entities, financial institutions, and large enterprises. The company offers a comprehensive suite of products, including the SevOne Data Platform, which gathers multi-vendor network performance metrics and flow data, and the SevOne Data Insight, designed for customizable visualizations and workflows. Additionally, the SevOne Data Appliance analyzes network and infrastructure data, while the SevOne Data Bus streams real-time data. The SevOne Data Cloud provides both real-time and historical insights from network telemetry. The company also has solutions for monitoring software-defined networking (SDN) and SD-WAN for managed services providers. Founded in 2003 and headquartered in Boston, Massachusetts, SevOne has expanded its presence with additional offices in Newark, Delaware, and London, United Kingdom. As of late 2019, SevOne operates as a subsidiary of Turbonomic, Inc.
Invoke Solutions specializes in real-time online research services that provide fast and actionable insights for a variety of clients. Their offerings include online and mobile applications that facilitate the integration of qualitative and quantitative research, enabling businesses to conduct extensive brand, communications, and product research. The company's technologies support diverse research needs, such as communications testing, product concept testing, brand equity assessment, and consumer experience analysis. With a client roster that includes major companies like Microsoft, Verizon, and Nestle, Invoke Solutions aims to enhance decision-making processes by delivering consumer-driven insights that inform strategic planning and execution.
Bright Horizons Family Solutions is a prominent provider of early education and child care services, focusing on employer-sponsored programs that assist employees in balancing their work and family responsibilities. The company operates through three main segments: full-service center-based child care, backup care, and educational advisory services. The majority of its revenue comes from full-service center-based child care, which encompasses traditional early education and care. In addition to these core offerings, Bright Horizons also provides in-home child and elder care, tuition assistance, and education consulting. With a strong presence in North America, the organization emphasizes nurturing children's unique qualities, fostering partnerships with families, and collaborating with employers to create family-friendly workplaces. This commitment extends to promoting professionalism, growth, and diversity within its work environment while ensuring financial stability.
GameLogic innovates games, promotions and marketing interfaces to help casino operators communicate and interact with their customers when they are away from the casino, ultimately establishing deeper bonds of player loyalty leading to increased casino visitation.
CentrePath, Inc. is a provider of intelligent management solutions for optical and storage networks, previously known as GiantLoop Network. The company specializes in helping organizations build and manage these networks, focusing on improving service availability while minimizing management costs. CentrePath's solutions are designed for mission-critical environments, ensuring business continuity and supporting the convergence of voice, video, and data. The company markets its data center networking solutions to various industries, including healthcare, financial services, media, and entertainment. Their services encompass critical networking functions such as event correlation, root cause identification, impact analysis, and performance monitoring. This enables clients to effectively conduct network staging, certification, space design, fiber testing, project management, and network transport services.
Network Intelligence
Series C in 2005
Network Intelligence Corporation provides security information and event management solutions. Its products include enVision that collects and protects data, as well as provides security and compliance analysis, and reporting and alerting solutions; Intelligence Engine software/hardware network security appliances for security information and event management market; and LogSmart Internet Protocol Database, which provides architecture to collect and protect the data from various Internet protocol devices. The company's strategic partners include Microsoft; NetworkAppliance; IBM; EMC2; EDS; Check Point Software Technologies, Ltd.; and Juniper Networks. Network Intelligence Corporation was formerly known as OpenSystems.com, Inc. and changed its name to Network Intelligence Corporation. The company was founded in 1996 and is headquartered in Westwood, Massachusetts. It also has offices in Rancho Santa Margarita, California; Chicago, Illinois; Alpharetta, Georgia; Seabrook, Texas; Arlington, Virginia; Amsterdam, the Netherlands; Paris, France; and London.
ProfitLogic engages in the development and marketing of retail profit optimization software solutions. It offers retail profit optimization, price optimization, and inventory planning software solutions for all retail verticals, which include assortment and allocation, pricing, in-season inventory management, promotions and marketing, and performance assessment and management solutions. The company provides applications to help retailers make profitable allocation, planning, and pricing decisions; and a marketer of profit optimizations systems. ProfitLogic, Inc. was formerly known as Technology Strategy, Inc. (TSI). The company was founded in 1983 and is based in Cambridge, Massachusetts.
deNovis Inc. is a leading provider of advanced transaction processing and information management solutions for the health insurance and health care benefits administration industry. deNovis's highly innovative claims processing and data management software enables commercial and government health plans to reduce administrative costs, expand their range of products and services, increase speed-to-market of new products and enhance the quality of customer service. The company's flagship software product—eHD™—serves as the core administrative platform for health plans and is designed to deliver the sophistication necessary to meet both existing and emerging needs of commercial, Medicare and Medicaid healthcare benefits administrators. deNovis is also known for its technical innovations, including HICL™ technology, which allows complex healthcare transaction systems to be programmed by business analysts rather than computer programmers, using English language commands and the actual policies and business rules of the health plan. deNovis's customer roster includes large commercial insurers and the U. S. Department of Health and Human Services—the nation's largest purchaser of healthcare and a provider of healthcare benefits to almost 80 million Americans. The company's strategic alliance partners include IBM Corporation and Deloitte Consulting. deNovis enterprise solutions for health plans are available for installation at customer locations or can be delivered on an outsourced or remote-hosted basis. The company is privately held and is headquartered in Lexington, Massachusetts.
ProfitLogic engages in the development and marketing of retail profit optimization software solutions. It offers retail profit optimization, price optimization, and inventory planning software solutions for all retail verticals, which include assortment and allocation, pricing, in-season inventory management, promotions and marketing, and performance assessment and management solutions. The company provides applications to help retailers make profitable allocation, planning, and pricing decisions; and a marketer of profit optimizations systems. ProfitLogic, Inc. was formerly known as Technology Strategy, Inc. (TSI). The company was founded in 1983 and is based in Cambridge, Massachusetts.
deNovis Inc. is a leading provider of advanced transaction processing and information management solutions for the health insurance and health care benefits administration industry. deNovis's highly innovative claims processing and data management software enables commercial and government health plans to reduce administrative costs, expand their range of products and services, increase speed-to-market of new products and enhance the quality of customer service. The company's flagship software product—eHD™—serves as the core administrative platform for health plans and is designed to deliver the sophistication necessary to meet both existing and emerging needs of commercial, Medicare and Medicaid healthcare benefits administrators. deNovis is also known for its technical innovations, including HICL™ technology, which allows complex healthcare transaction systems to be programmed by business analysts rather than computer programmers, using English language commands and the actual policies and business rules of the health plan. deNovis's customer roster includes large commercial insurers and the U. S. Department of Health and Human Services—the nation's largest purchaser of healthcare and a provider of healthcare benefits to almost 80 million Americans. The company's strategic alliance partners include IBM Corporation and Deloitte Consulting. deNovis enterprise solutions for health plans are available for installation at customer locations or can be delivered on an outsourced or remote-hosted basis. The company is privately held and is headquartered in Lexington, Massachusetts.
Maximize your return on self-service system investments iPhrase® Technologies, Inc. is the leading provider of self-service search and navigation software for mission-critical applications. Their One Step™ platform simplifies access to all your high-value information. Through a unique combination of technologies, including natural language processing, multi-source retrieval, dynamic presentation, and in-depth analytics, One Step delivers an online search and navigation experience that is second to none. With One Step, your customers and employees will see a clear difference—with superior relevancy and usability in search results that leverage all your product, service, and information assets. Whether in data, documents, or applications, One Step covers all your information resources. With One Step, you will see a far better return on your technology investments with a self-service search solution that supports and works with your existing systems. The business results are clear—increased revenue, decreased costs, improved customer satisfaction, and increased productivity. Their goal is simple—they want to help you deliver an online experience that equals that found in person or through higher-cost channels, such as e-mail, chat, and phone. iPhrase is proud to deliver a powerful ROI for critical applications at such leading companies as Charles Schwab & Co., Neiman Marcus, LexisNexis and TD Waterhouse. Their investors include Charles River Ventures, Greylock, Reed Elsevier Ventures, Sequoia Capital, TD Capital Technology Ventures, and Bain Capital. Founded by former MIT researchers and business leaders, iPhrase has offices in Cambridge, MA and San Mateo, CA.
Solect Energy is a provider of commercial solar energy solutions based in Massachusetts, USA. The company specializes in the installation, financing, and maintenance of solar energy systems for commercial, public, and nonprofit organizations. Solect Energy adopts a collaborative approach to develop tailored solutions that align with clients' financial needs and business objectives. Additionally, the company assists clients in securing financing and incentives to help lower electricity costs. With a robust portfolio of completed solar projects, Solect Energy focuses exclusively on commercial installations and does not engage in residential projects.
Cortera is a provider of comprehensive business-to-business payment and purchase behavior data and insights on public and private companies. The company tracks $1.6 trillion in business-to-business purchases across 45 spend categories to deliver insights on 20 million U.S. business locations. Cortera's solutions enable companies of all sizes to better understand their customers, suppliers and business partners by gaining visibility into what they purchase, how they pay and how their purchase and payment behavior changes over time. Thousands of companies across diverse industries use Cortera solutions to increase revenue, improve sales and marketing effectiveness, and reduce risk. Cortera is privately held with offices in Boca Raton, Florida; Boston and Quincy, Massachusetts and Bangalore, India.